A Biotech Breakthrough Means Big Gains for These 2 Stocks

A Biotech Breakthrough Means Big Gains for These 2 Stocks

Investors on Wall Street continued to have doubts about when the stock market is likely to recover, as ongoing worries about inflation, interest rates, and the global financial system have everyone on edge. Biotech stocks have been among those hit hardest by the bear market in 2022, but Biogen (NASDAQ: BIIB) announced good news in a key clinical trial that has huge implications for those suffering from a harsh and debilitating disease. Biogen's favorable outcome also gave industry peer Eli Lilly (NYSE: LLY) a boost, on optimism that a new way of coming up with important treatments could spur further successes.